Biotechnology New Star "Cellatopia" Successfully Won Seed Round Financing of Nearly 10 Million RMB
Recently, a young biotechnology company in Suzhou Industrial Park Suzhou Cellatopia Biotechnologies Co., Ltd(hereinafter referred to as "Cellatopia") announced that it has successfully obtained seed round financing of nearly 10 million yuan.
this financingSuzhou Shishangbai Venture Partnershipled the investment, Suzhou Nuo for Venture Capital Co., Ltd. and other institutions to invest. They spoke highly of Cellatopia's product design concept, innovative R & D strength, market prospects and team capabilities, and expressed their willingness to cooperate for a long time. The participation of these investors not only provides valuable financial support for Cellatopia, but also injects strong confidence into its future development.
Cellatopia was established in July 2023 and is committed to developing innovative biomedical tools to solve the current problems of low repeatability and reliability at the R & D end and unsmooth technical docking between research results and industrialization. Cellatopia focuses its optimization on high uncertainty such as cell culture and processing, and strives to meet multi-scenario parallel applications and standardized operations while taking into account supply chain and cost optimization, so that the precisely controlled cell culture and processing system can benefit more research laboratories and clinical application terminals. In the design of the system, Cellatopia Bio did not use common integrated solutions, but redesigned and developed each operation link according to the latest life science cognition. Regarding such implementation strategies, Dr. Li Jingyu, founder and CEO of Cellatopia, explained: "First of all, many of the tools we use now are outdated and cannot adapt to new life science research and applications. Secondly, now the domestic industrial chain is relatively complete, R & D personnel reserves are sufficient, in the case of proper operation and management of the cost of redeveloping new tools is not as high as expected, but because of a more reasonable supply chain combination to reduce the price of products. Finally, we now have the ability to design and manufacture products with excellent performance and international leading level, not just the localization of foreign products."
At present, Cellatopia has completed the technical feasibility verification of the product. This round of seed funding will support the development of the prototype of the same biological.
For the success of this financing, Dr. Jingyu Li said: "We are very grateful for the trust and support of investors. This seed capital will provide a significant impetus for our company's innovative product development and commercialization process. We will uphold the concept of innovation, flexibility, diversity and integrity, and strive to create the best tools for biomedical colleagues."
Regarding this investment, Dang Feng, head of Suzhou Shishangbai Venture Partnership, said: "Shishangbai is very honored to cooperate with Dr. Li Jingyu. From the first day of its establishment, the goal of Cellatopia is to solve the real pain points and difficulties in the life science and pharmaceutical industries, accelerate the process of the entire industry, and generate sufficient commercial value. Dr. Li has many years of excellent R & D and management experience, and has experienced many management functions. He is a rare entrepreneur with profound experience in technology and management in the industry. We look forward to Xitong Biology under her leadership to produce more influential work in the industry and benefit more fields."
information, the R & D team of Xitong Bio has achieved a series of important research results, and will complete the development of prototype products and the marketization of new products within this year. We have reason to believe that in the near future, Xitong Biology will make more brilliant achievements in the field of biomedicine by virtue of its excellent technical strength and innovation ability.
>>>>>About Suzhou Shishangbai Venture Capital
Suzhou Shishangbai Venture Capital is an early service organization in the field of life sciences (Biotech & Medtech), founded by a number of industry veterans in 2022.
Through the understanding of the whole life cycle of innovative enterprises and the ability to serve, Suzhou Shishangbai Venture Capital accelerates the double drive with investment incubation, and fully supports the best entrepreneurs it can find with the help of the introduction of overseas innovative companies and scientific research resources.
Suzhou Shishangbai Venture Capital is striving to become the most important partner of a group of world-leading BioTech and MedTech companies in Suzhou and the Yangtze River Delta.Connecting Amazing Peopledelivers confidence and conviction to help nurture a group of global leaders in the life sciences sector to become enablers of affordable medical technology.
